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Abstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), espe-
cially when carbapenem resistant, have been very difficult to manage in the last fifteen years, 
owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cepha-
losporin recently approved by the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps 
in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro 
activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases 
producers. Clinical data from both registrative studies and post-marketing experiences are 
essential to confirm whether these promises from in vitro studies could readily translate into 
clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the 
treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to 
provide both randomized controlled trials (RCT) and real-life data to improve the ability of 
clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB 
infections. In this narrative review, we discuss the emerging data from pivotal RCT and 
initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB 
infections. 
Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, 
antimicrobial resistance
Introduction
Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), espe-
cially when carbapenem resistant, have been very difficult to manage in the past 
fifteen years, owing to the paucity of therapeutic options.1–5 Furthermore, available 
options such as polymyxins, aminoglycosides, and/or glycylcyclines, although 
certainly useful in presence or resistance to all other classes, have some disadvan-
tages that clinicians would like to avoid, including nonnegligible toxicity and 
possible suboptimal pharmacokinetics in some sites of infection.6–8
Some precious additions to the antibiotic armamentarium such as ceftazidime/ 
avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/rele-
bactam have recently allowed to renew the availability of β-lactam antibiotics (that 
usually display good safety profiles and pharmacokinetics) for treating some MDR- 
GNB.9–12 However, some gaps still need to be filled, for example, restoring the 
activity of β-lactams against metallo-β-lactamases (MBL)-producing GNB and 
carbapenem-resistant Acinetobacter baumannii.
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In this narrative review, we discuss the available anti-
microbial, pharmacological, and clinical data for cefider-
ocol, a siderophore cephalosporin recently approved by the 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) that may have the potential to 
fill some of the remaining gaps in the treatment of MDR- 
GNB infections.
Methods
The structure of the present narrative review was agreed 
by all authors and articulated in the following sections: (i) 
antimicrobial properties; (ii) pharmacological properties; 
(iii) results of randomized clinical trials: efficacy; (iv) 
safety of cefiderocol; (v) case reports and case series; 
(vi) place in therapy. Then, the authors were divided in 
small groups in order to draft the different sections, sup-
ported by inductive PubMed searches for relevant publica-
tions. Eventually, the different drafts were merged into 
a final manuscript that was approved by all authors.
Antimicrobial Properties
Cefiderocol is a novel siderophore cephalosporin active 
against GNB, including strains of Enterobacterales and 
nonfermenters that exhibit difficult-to-treat (DTR) resis-
tance phenotypes (ie, resistant to fluoroquinolones and 
older β-lactams including carbapenems).13,14 This notable 
and thus far unique spectrum of activity is dependent on 
the following features: i) uptake across the bacterial outer 
membrane also via iron transporters, thus enhancing accu-
mulation of the drug in the periplasmic space and over-
riding resistance mechanisms such as efflux pumps and 
porin alterations; and ii) remarkable stability, likely con-
ferred by modifications in the C-7 and C-3 side chains, 
against all classes of beta-lactamases, including carbape-
nemases (both serine carbapenemases, such as KPC and 
OXA-types, and metalloenzymes such as NDM, VIM, 
IMP and the intrinsic L1 carbapenemase of 
Stenotrophomonas maltophilia).15–18
Similar to cefepime, cefiderocol carries a pyrrolidinium 
group on the C3 side chain, which enhances stability to β- 
lactamases and antimicrobial activity. Moreover, similar to 
ceftazidime, cefiderocol carries an aminothiazole ring and 
a carboxypropyl-oxyimino group on the C7 side chain, 
which also enhances stability to β-lactamases and activity 
against Gram-negative bacilli, including Pseudomonas 
aeruginosa. In addition, cefiderocol harbors 
a chlorocatechol group at the end of the C3 side chain, 
which is able to chelate ferric iron and confers siderophore 
activity: the complex cefiderocol-Fe3+ can thus be actively 
transported into the periplasmic space by specific iron- 
transporters, such as PiuA in P. aeruginosa, unlike other 
beta-lactams which only enter by passive diffusion across 
porin channels.14,18 Indeed, resistance acquisition studies 
revealed that mutations causing increased levels of pyo-
verdine production or higher level of FecA expression 
(both involved in the iron transport system) were asso-
ciated with increased cefiderocol minimum inhibitory con-
centration (MIC) values in P. aeruginosa.19 Once in the 
periplasmic space, cefiderocol exerts its antimicrobial 
activity by inhibition of the penicillin-binding proteins 
(PBP)-mediated cell wall synthesis, leading to cell 
death.14,18 Cefiderocol was shown to have high affinity 
for PBP3 in clinically relevant Gram-negative rods (eg, 
Klebsiella pneumoniae, Escherichia coli, P. aeruginosa, 
and Acinetobacter baumannii), and also for PBP2 in 
K. pneumoniae and for PBP1a in P. aeruginosa.20,21
Similar to cefepime, cefiderocol is a weak AmpC indu-
cer (possibly due to low PBP4 binding) with low affinity 
for chromosomal AmpC-type β-lactamases,22 which 
account for its overall good activity also against AmpC 
overproducing strains. Mutations causing alteration or loss 
of porin channels, such as OmpK35 and OmpK36 in 
K. pneumoniae, are associated with a marginal decrease 
of cefiderocol antimicrobial activity,18 while inactivation 
of the MexAB-OprM efflux pump only causes a slight 
cefiderocol MIC decrease in P. aeruginosa, suggesting 
that this mechanism is unable to efficiently expel the 
molecule outside the microbial cell.20
During infections, an iron depleted-milieu is expected to 
be encountered in the host tissues in response to which the 
bacterial iron transporters are up-regulated.23 This should 
be accounted for when testing in vitro susceptibility to 
cefiderocol, which must be carried out using iron-depleted 
media when using reference broth microdilution. The 
growth medium is prepared by treating conventional cation- 
adjusted Mueller-Hinton broth with a cation-binding resin 
in order to remove all the cations, and subsequently replen-
ishing the cation-depleted broth with adequate concentra-
tions of Mg2+, Zn2+ and Ca2+.24–26
For cefiderocol, the Clinical and Laboratory Standards 
Institute (CLSI) has set clinical breakpoints (CB) for 
Enterobacterales, P. aeruginosa, S. maltophilia, and 
A. baumannii, with MIC values of ≤4, 8, and ≥16 mg/L 
for susceptible, intermediate, and resistant categories, 
respectively.24 However, these breakpoints were not 
accepted by FDA for A. baumannii and S. maltophilia, 
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since these two species were not included in the Apeks- 
UTI clinical trial that was designed for the approval of the 
drug in the USA.27 In Europe, the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) has 
set cefiderocol CB with MIC values of ≤2 mg/L and 
>2 mg/L for susceptible and resistant categories, respec-
tively, for both Enterobacterales and Pseudomonas spp., 
and also apharmacokinetic/pharmacodynamic (PK/PD) 
breakpoint MIC value of ≤2 mg/L for susceptibility, 
while CB was not set for A. baumannii and 
S. maltophilia due to insufficient clinical evidence.25 
Epidemiological cut-off (ECOFF) values were also 
defined by the EUCAST as follows: 0.25 mg/L for 
E. coli, K. pneumoniae, and A. baumannii; 0.5 mg/L for 
P. aeruginosa, and 0.06 mg/L for S. maltophilia.25
Cefiderocol susceptibility has been investigated in large 
international surveillance studies carried out since 2014 
(SIDERO-WT studies), covering over 28,000 Gram- 
negative isolates.13 Overall, the MIC90 for 
Enterobacterales (including E. coli, Klebsiella spp., 
Citrobacter spp., Enterobacter spp., Serratia spp., 
Morganella morganii, and Proteus spp.) ranged from 0.25 
to 1 mg/L, with no significant geographical or temporal 
differences. Cumulative activity against Enterobacterales 
from surveillance studies revealed that >98% and >99% of 
isolates were inhibited at concentrations of 2 mg/L and 
4 mg/L, respectively. Activity was retained against most 
isolates resistant to expanded-spectrum cephalosporins and 
carbapenems, including those producing different types of 
serine carbapenemases and metallo-β-lactamases. The 
MIC90 of Enterobacterales was 2–16 mg/L for strains pro-
ducing different types of carbapenemases (Table 1). Against 
1022 carbapenem-nonsusceptible Enterobacterales, of 
which 23% ceftazidime/avibactam resistant and 22% colis-
tin resistant, cefiderocol MIC90 was 4 mg/L and 97% of the 
isolates were inhibited at a concentration of 4 mg/L.28
Data for Gram-negative nonfermenters from the inter-
national surveillance studies (see Table 1) reported MIC90 
values of 0.5–2 mg/L for P. aeruginosa, 1–2 mg/L for 
Acinetobacter spp., 0.25–0.5 mg/L for S. maltophilia, 
and 0.12–0.5 mg/L for Burkholderia cepacia complex, 
underscoring the remarkable activity of cefiderocol against 
these difficult-to-treat pathogens. Cumulative activity data 
revealed that >99%, >95%, and >95% of isolates of 
P. aeruginosa, A. baumannii, and B. cepacia complex 
from surveillance studies, respectively, were inhibited at 
a concentration of 4 mg/L, while >99% of isolates of 
S. maltophilia were inhibited at a concentration of 2 mg/ 
L. Activity was retained against most P. aeruginosa iso-
lates resistant to carbapenems (>98% inhibited at 2 mg/L), 
including those resistant to ceftolozane/tazobactam and 
producing metalloenzymes. A notable activity was also 
retained against carbapenem-resistant A. baumannii, with 
an MIC90 of 1 mg/L for isolates producing OXA-type 
carbapenemases (Table 1).
Few isolates with elevated cefiderocol MIC values 
(≥8 mg/L) were detected from large surveillance studies. 
Some of these isolates were NDM-1 metallo-β-lactamase or 
PER-1 extended-spectrum β-lactamase producers; in such 
cases, the addition of enzyme inhibitors (eg, dipicolinic acid 
and/or avibactam) was capable of reducing cefiderocol MIC 
values, suggesting that production of these β-lactamases 
may contribute to increased cefiderocol MICs. However, 
cefiderocol exhibited good activity against several isolates 
producing these enzymes,29 suggesting that the presence of 
additional resistance mechanisms is likely necessary to 
increase MIC values above the susceptibility breakpoint.
Concerning other pathogens, cefiderocol was shown to 
be active in vitro against Vibrio spp. Haemophilus influen-
zae, Moraxella catarrhalis, and Bordetella 
parapertussis,20 and also against less common Gram- 
negative pathogens including Pantoea spp., 
Sphingomonas paucimobilis, and Elizabethkingia 
meningoseptica.30 On the other hand, activity is variable 
against anaerobes, likely due to the variable importance of 
the siderophore-iron transport systems for growth under 
anaerobic conditions.20
In conclusion, cefiderocol is a new antibiotic with 
a unique mechanism of cell entry in Gram-negative patho-
gens, while being stable to most beta-lactamases. It is 
a potentially useful drug for treating infections caused by 
carbapenemase-producing Enterobacterales and non- 
fermenters. As such, cefiderocol appears to be one of the 




The pharmacokinetic profile of cefiderocol was studied in 
healthy subjects both after single-ascending dose (100 to 
1000 mg) and multiple-ascending dose (1000 mg q8h and 
2000 mg q8h).31 Overall, cefiderocol showed a linear phar-
macokinetic behavior with ascending doses and a mean 
elimination half-life of 2.0–2.7h. The mean total clearance 
was of 4.6–6.0 L/h and the fraction excreted unchanged 
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into urine was of 60–70%. The pharmacokinetic character-
istics of cefiderocol at the dose of 2000 mg q8h over 1 h in 
healthy subjects are summarized in Table 2.31
The pharmacokinetics of cefiderocol was compared in 
healthy subjects with those in subjects with mild [esti-
mated glomerular filtration rate (eGFR) 60-<90 mL/min/ 
Table 1 Susceptibility to Cefiderocol of Gram-Negative Isolates from Selected Surveillance Studies
Order/Genus/Speciesa (No. 
Isolates)
Sourceb (Years) MIC (mg/L) % Inhibited at 
4 mg/Lc




Enterobacterales 3007 NAm (2014–15) ≤0.002–8 0.5 NRe NR [73]
Enterobacterales 3080 EU (2014–15) ≤0.002–8 1 NR NR [73]
Enterobacterales 2470 NAm (2015) ≤0.002–128 0.5 NR NR [74]
Enterobacterales 3543 EU (2015) ≤0.002–8 1 NR NR [74]
Enterobacterales 20,949 Cumulative (2014–16) ≤0.002–>256 NR 99.4 98.6 [71]
P. aeruginosa 1530 NAm/EU (2014–15) ≤0.002–8 0.5 NR NR [73]
P. aeruginosa 1540 NAm/EU (2015) ≤0.002–8 0.5 NR NR [74]
P. aeruginosa 4942 Cumulative (2014–16) ≤0.002–8 2 99.9 NR [71]
A. baumannii 1148 NAm/EU (2014–15) ≤0.002–64 1 NR NR [73]
Acinetobacter spp. 308 NAm (2015) ≤0.002–>256 1 NR NR [74]
Acinetobacter spp. 664 EU (2015) ≤0.002–>256 2 NR NR [74]
A. baumannii 2896 Cumulative (2014–16) ≤0.002–256 2 95.6 NR [71]
S. maltophilia 152 NAm (2014–15) ≤0.002–4 0.5 100 NR [73]
S. maltophilia 276 EU (2014–15) 0.004–2 0.25 100 100 [73]
S. maltophilia 165 NAm (2015) 0.004–64 0.5 NR NR [74]
S. maltophilia 175 EU (2015) ≤0.002–64 0.25 NR NR [74]
S. maltophilia 217 Global (2014–16) 0.004–2 0.25 100 100 [28]
S. maltophilia 1173 Cumulative (2014–16) ≤0.002–64 0.25 99.8 99.6 [71]
B. cepacia complex 40 NAm (2015) ≤0.002–32 0.5 NR NR [74]
B. cepacia complex 49 EU (2015) ≤0.002–32 0.12 NR NR [74]
B. cepacia complex 164 Cumulative (2014–16) ≤0.002–64 0.25 95.7 NR [71]
Enterobacterales Carba-NS 1020 Global (2014–16) 0.004–32 4 NR NR [28]
Enterobacterales KPC+ 75 NAm/EU (2014–15) 0.03–4 2 NR NR [75]
Enterobacterales KPC-2+ 355 NR ≤0.03–32 8 NR NR [76]
Enterobacterales KPC-3+ 380 NR ≤0.03–64 2 NR NR [76]
Enterobacterales OXA-48+ 154 Global (2000–16) 0.03–64 2 NR NR [77]
Enterobacterales MBL 
(VIM, NDM, IMP)+
69 Global (2000–11) ≤0.12–>16 16 89.8 86.9 [78]
Enterobacterales MBL 
(VIM, NDM, IMP)+
134 Global (2000–16) 0.03–64 4 NR NR [77]
Enterobacterales ESCR 2547 Cumulative (2014–16) NR NR 99.1 91.3 [71]
P. aeruginosa Carba-NS 
and CTZ-NS
1005 Global (2014–16) 0.004–32 4 NR NR [28]
P. aeruginosa Carba-NS 1154 Cumulative (2014–16) NR NR 99.9 98.5 [71]
P. aeruginosa Carba-NS 
MBL+
30 NAm/EU (2014–15) 0.008–2 2 NR NR [75]
A. baumannii Carba-NS 
OXA-23/24/58+
681 NAm/EU (2014–15) ≤0.002–64 1 NR NR [75]
A. baumannii Carba-NS 1891 Cumulative (2014–16) NR NR 94.8 91.8 [71]
Notes: aCarba-NS, carbapenem nonsusceptible; CTZ-NS, ceftolozane-tazobactam nonsusceptible; ESCR, resistant to expanded-spectrum cephalosporins (cefepime MIC >4 mg/ 
L). bNAm, North America; EU, Europe. cCLSI susceptibility breakpoint for Enterobacterales, P. aeruginosa, Acinetobacter spp., and S. maltophilia. dEUCAST susceptibility breakpoint for 
Enterobacterales and P. aeruginosa. eNR, not reported.
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1.73 m2], moderate (eGFR 30-<60 mL/min/1.73 m2) and 
severe impairment of renal function (eGFR <30 mL/min/ 
1.73 m2) after a single dose of 1000 mg.32 Overall, total 
drug clearance and elimination half-life were inversely and 
linearly related with renal dysfunction. The mean ratio of 
drug exposure, in terms of area under the concentration– 
time curve from zero-to-infinity (AUC0-∞), in subjects 
with mild, moderate, and severe renal impairment com-
pared with those with normal renal function was 1.0, 1.5, 
and 2.5. The volume of distribution (Vd) and the fraction 
unbound (fu) to the plasma proteins were very similar 
between groups (mean Vd ranged from 13.5 to 16.4 L; 
mean fu ranged from 0.42 to 0.35).32
The potential for drug–drug interaction of cefiderocol 
with different human drug transporters [organic anion 
transporter (OAT) 1 and 3, organic cation transporter 
(OCT) 1 and 2, multidrug and toxin extrusion (MATE) 
2-K and organic anion transporting polypeptide (OATP) 
1B3] was assessed in three cohorts of healthy subjects.33 
Substrates of these transporters were administered conco-
mitantly to cefiderocol for assessing whether cefiderocol 
might or not inhibit drug transport. Overall, the study did 
not show any clinically significant drug–drug interaction 
of cefiderocol via drug transporters.33
The intrapulmonary pharmacokinetics of cefiderocol 
was assessed in healthy adult subjects after administration 
of a single 2000 mg dose infused over 1 h.34 The mean 
epithelial lining fluid (ELF)-to-plasma ratio was of 0.101 
and 0.239 based on total drug in plasma and on free drug 
in plasma, respectively, similar to other cephalosporins.34
A recent study assessed the concentration-time profile 
of total radioactivity equivalent and unchanged cefiderocol 
after administration of 1000 mg [14C] cefiderocol over 1 
h in healthy subjects.35 The findings showed that cefider-
ocol accounted for 92.3% of total radioactivity in plasma 
and for 90.6% of the administered dose into urine, thus 
confirming that metabolism is a minor route of elimination 
of cefiderocol.35
Pharmacodynamic Properties
Cefiderocol is a beta-lactam antibiotic for which the phar-
macodynamic determinant of efficacy is the time that the 
plasma concentration exceeds the MIC of the pathogen 
(t>MIC) during the dosing interval.36 Experimental ani-
mal models of infections showed that a t>MIC of around 
75% is associated with an effective microbiological 
response to cefiderocol in terms of 1–2 log of bacterial 
killing.36,37 In a P. aeruginosa neutropenic murine model, 
the t>MIC targets needed for stasis, 1 log and 2 log 
decrease in bacterial burden against strains with MICs of 
0.064–0.5 mg/L ranged 44.4–94.7%, 50.2–97.5%, and 
62.1–100%, respectively.36 In murine thigh and lung 
infection models, the mean t>MIC needed for 1-log reduc-
tion in bacterial burden against various Gram-negative 
bacteria (E. coli, K. pneumoniae, P. aeruginosa, 
A. baumannii, and S. maltophilia) differed according to 
the site of infection and to the pathogen.37 In the thigh 
infection model, the mean t>MIC was of 73.3% and 
77.2% against Enterobacterales and P. aeruginosa, 
respectively; in the lung infection model, it was of 
64.4%, 70.3%, 88.1%, and 53.9% against 
Enterobacterales, P. aeruginosa, A. baumannii, and 
S. maltophilia, respectively.
Matsumoto et al assessed in an immunocompetent rat 
respiratory tract infection model the influence that infusion 
time of administration (3 h vs 1 h) may have on the 
efficacy of humanized cefiderocol exposure (2g q8h) 
against carbapenem-resistant Gram-negative bacilli 
(P. aeruginosa, A. baumannii and K. pneumoniae). 
Administration by extended infusion (EI) over 3 
h resulted in more sustained reduction in lung bacterial 
burden (3.04–4.41 log10) compared with intermittent infu-
sion (II) over 1 h (0.7–3.7 log10).38 This provided the 
rationale for considering the use of EI for ameliorating 
t>MIC with cefiderocol.
Consistently, the efficacy of humanized exposures of 
2g q8h EI over 3 h cefiderocol was assessed against 
various species of Gram-negative bacteria with variable 
patterns of susceptibility to other antibiotics in several 
murine neutropenic thigh infection models.39–43 Monogue 
Table 2 Dosage Regimens of Cefiderocol Focused at Achieving 
90% of PTAs of 75% T>MIC Against Pathogens with an MIC Up 
to 4 mg/L in Patients with Different Classes of Renal Function44
CLCr Dosage Regimen
≥ 120 mL/min° (ARC) 2g q6h over 3h
≥ 90 mL/min/1.73 m2* 2g q8h over 3h
60-<90 mL/min/1.73 m2* 2g q8h over 3h
30-<60 mL/min/1.73 m2* 1.5 g q8h over 3h
15 to 30 mL/min/1.73 m2* 1 g q8h over 3h
< 15 mL/min/1.73 m2* 0.75 g q12h over 3h
IHD** 0.75 g q12h over 3h
Notes: °Estimated by means of the Cockcroft and Gault formula. *Estimated by 
means of the modified diet renal diseases (MDRD) formula. **A supplemental dose 
of 0.75g over 3h should be administered after completion of IHD on the dialysis day. 
Abbreviations: ARC, augmented renal clearance; CLCr, creatinine clearance; IHD, 
intermittent hemodialysis.
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and colleagues assessed the efficacy of cefiderocol against 
a collection of 15 P. aeruginosa, A. baumannii, and 
Enterobacterales isolates. They found that the humanized 
exposures of cefiderocol were able to cause a ≥1-log drop 
in bacterial burden against all pathogens with an MIC up 
to 4 mg/L.42 Similar findings were observed also by Ghazi 
and colleagues who assessed the efficacy of humanized 
exposures of cefiderocol against eight different strains of 
P. aeruginosa with an MIC ranging from 0.063 to 0.5 mg/ 
L for cefiderocol, from 2 to 64 mg/L for cefepime, and 
from 1 to 32 mg/L for levofloxacin.40 Stainton and collea-
gues assessed the sustainability of humanized exposure of 
cefiderocol over 72 h against a collection of 12 
P. aeruginosa, A. baumannii, and Enterobacterales iso-
lates. Sustained kill was observed at 72 h against 9 out 
of 11 strains with an MIC ranging from 0.5 and 8 mg/L, 
and no adaptive resistance was observed during therapy.43 
In another study, the effect of cefiderocol human-simulated 
exposures was compared with that of ceftazidime human- 
simulated exposures (2g q8h over 2 h) against 24 
S. maltophilia strains that were fully susceptible to cefi-
derocol (MICs 0.015–0.5 mg/L) and either ceftazidime- 
susceptible (10/24) or ceftazidime-nonsusceptible (14/24). 
For cefiderocol bacterial killing was potent against all 
strains (mean ± SD bacterial burden log10 reduction at 24 
h - 2.76 ± 0.68; ≥2 log in 87.5% and ≥1 log in the 
remaining 12.5% of isolates) whereas for ceftazidime it 
was present but less potent against the 10 ceftazidime- 
susceptible strains (- 1.38 ± 1.49) and absent against the 
14 ceftazidime-nonsusceptible strains (mean ± SD bacter-
ial growth of 0.64 ± 0.79).39 Recently, a neutropenic thigh 
infection model confirmed that the efficacy of humanized 
cefiderocol exposure at 72 h against Enterobacterales, 
P. aeruginosa, and A. baumannii isolates is unaltered 
even by host iron overload (mean ± SD log10 bacterial 
decrease – 2.5 ± 1.5 vs – 2.5 ± 1.4 in standard and iron- 
overloaded models, respectively).41 Consistently with 
these findings, the dosage regimens proposed for cefider-
ocol were focused at predicting by means of Monte Carlo 
simulations a high probability of success (≥90% of PTAs 
of 75% t>MIC) against pathogens with an MIC up to 
4 mg/L in patients belonging to all of the different classes 
of renal function (Table 2).44
Noteworthy is that cefiderocol is one of the few anti-
biotics in the therapeutic armamentarium with a well- 
defined dosing strategy specified in the manufacturer’s 
fact sheet also for patients with augmented renal clearance 
(ARC). ARC is defined as a CLCr >120–130 mL/min/ 
1.73 m2 and is a pathophysiological condition that may 
accelerate the elimination of beta-lactams like cefiderocol, 
thus theoretically causing underexposure if standard 
dosages are administered.45 The strategy of a more inten-
sified dosage is extremely relevant in preventing the risk 
of therapeutic failure associated with drug underexposure 
when using cefiderocol in populations of critically ill 
patients at high prevalence of ARC, like those with febrile 
neutropenia (16.4%), sepsis (39.5–56%), burns (65%), 
trauma (85%), and subarachnoid hemorrhage (100%).45
The strategy of administering cefiderocol by EI among 
all patients irrespective of the degree of renal function may 
be helpful also at minimizing the development of multi-
drug antimicrobial resistance. Administering beta-lactams 
by EI rather than by II may represent a step forward in 
suppressing resistance amplification, as it may ensure bet-
ter exposures in terms of t>MIC compared with II.46
Results of Randomized Clinical 
Trials: Efficacy
The efficacy of cefiderocol in complicated urinary tract 
infections (cUTI) was evaluated in a randomized (2:1), 
Phase II, double-blind, parallel-group, non-inferiority 
trial (APEKS-cUTI), started in 2014. In this trial, cefider-
ocol was compared with imipenem-cilastatin. Patients 
infected by carbapenem-resistant organisms were not 
enrolled. The primary endpoint was clinical cure/micro-
biological eradication (as a composite endpoint) at the test 
of cure (TOC), which was set at 7±2 days after the end of 
treatment (EOT). The study was planned with a non- 
inferiority margin of 20%. However, following discussion 
with the FDA on the possible decrease of the non- 
inferiority margin to 15% and the increase of the sample 
size, the study protocol was amended accordingly.47
The APEKS-cUTI study was conducted in 67 hospitals 
in 15 countries, from February 2015 to August 2016. Only 
individuals aged ≥18 years and with a diagnosis of cUTI 
(with or without pyelonephritis) or acute uncomplicated 
pyelonephritis (30% of the total sample size) were 
recruited. A one/two-week intravenous therapy was 
planned in the study protocol: cefiderocol (2 g) q8h vs 
imipenem-cilastatin (1g) q8h. Dosages were adjusted 
depending on renal function and body weight. The high 
dose of imipenem was chosen to allow inclusion of 
patients with P. aeruginosa infection.
A total of 371 patients were enrolled in the primary 
study population (modified intention-to-treat [mITT]). 
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More than half of patients were aged ≥65 years (in both 
arms) and complicated patients were more frequent than in 
contemporary studies. The most frequent uropathogens 
were E. coli and K. pneumoniae, whereas P. aeruginosa 
was isolated from 7% and 4% of patients treated with 
cefiderocol and imipenem-cilastatin, respectively. Several 
bacterial isolates were resistant to cefepime and levoflox-
acin. The primary endpoint was achieved by 73% (183/ 
252) and 55% (65/119) of the patients enrolled in the 
cefiderocol and imipenem-cilastatin arms, respectively 
(adjusted difference: 18.6%; 95% confidence interval 
[CI] 8.2 to 28.9, thereby demonstrating not only non- 
inferiority but also superiority of cefiderocol as a post 
hoc result). When analyzing the single components of the 
composite endpoint, microbiological response was higher 
in patients treated with cefiderocol (73% [184/252]) as 
opposed to those treated with imipenem-cilastatin (56% 
[67/119]), with an adjusted difference of 17.3% (95% CI 
6.9 to 27.6). Conversely, clinical response was similar in 
the two arms (90% [226/252] in cefiderocol-treated 
patients vs 87% [104/119] in the imipenem-cilastatin trea-
ted-patients; adjusted difference 2.4%, 95% CI −4.7 
to 9.4).
The efficacy of cefiderocol in patients with hospital- 
acquired bacterial pneumoniae (HABP), ventilator-associated 
bacterial pneumonia (VABP), or healthcare-associated bacter-
ial pneumonia (HCABP) caused by GNB was evaluated in the 
study APEKS-NP, a Phase III, double-blind, randomized, non- 
inferiority trial. The results of the APEKS-NP trial have been 
recently published.48,49 The patients were randomized to cefi-
derocol 2 g every 8 h or to meropenem 2 g every 8 h, both as 
a 3-h infusion. Linezolid was administered in both arms for 
a duration of at least 5 days while cefiderocol or meropenem 
was administered for 7–14 days. The primary endpoint was 
all-cause mortality at day 14 for the mITT population, with 
a non-inferiority margin of 12.5%. Cefiderocol was non- 
inferior to meropenem with respect to all-cause mortality 
at day 14 (12.4% [18/145] in cefiderocol arm vs 11.6% [17/ 
146] in meropenem arm; difference 0.8%; 95% CI −6.6 to 
8.2).48
The CREDIBLE-CR study was an open-label, interna-
tional, multicenter, Phase 3 RCT that was pathogen- 
oriented rather than indication oriented:50,51 this was 
a descriptive study, not powered for inferential testing. 
Indeed, cefiderocol was compared with best available 
therapy (BAT) for the treatment of severe infections 
(HCABP, HABP, VABP, cUTI, or bloodstream infections 
[BSI]/sepsis) due to carbapenem-resistant (CR) GNB. The 
results of the CREDIBLE-CR study have also been 
recently published.52 Cefiderocol 2 g every 8 h was 
given as a 3-h infusion and BAT was chosen by the 
investigator and consisted of up to three antibiotics. 
Patients were randomized 2:1 to receive cefiderocol or 
BAT. Duration of therapy (either with cefiderocol or 
with BAT) was 7 to 14 days, possibly extended up to 21 
days based on reasonable explanation. In patients with 
cUTI, a minimum length of therapy of 5 days was 
allowed. The primary efficacy endpoint for patients with 
HABP/VABP/HCABP and for those with BSI/sepsis was 
clinical cure at TOC visit. For patients with cUTI, the 
primary efficacy endpoint was microbiological cure (era-
dication) at TOC. In the CR-mITT population (primary 
study population) clinical cure rates at TOC were compar-
able between groups, overall (52.5% [42/80] in cefidero-
col-treated vs 50% [19/38] in BAT-treated patients) and in 
subgroups of patients with HABP/VABP/HCABP (50% 
[20/40] in cefiderocol-treated vs 52.6% [10/19] in BAT- 
treated patients), and patients with BSI/sepsis (43.5% [10/ 
23] in cefiderocol-treated vs 42.9% [6/14] in BAT-treated 
patients). Microbiological cure in patients with cUTI was 
52.9% (9/17) and 20% (1/5) in cefiderocol-treated and 
BAT-treated patients, respectively. However, all-cause 
mortality at day 14, day 28, and day 49 was numerically 
higher in the cefiderocol group (19%, 25%, 34%, respec-
tively) compared to BAT (12%, 18%, 18%, respectively). 
This mortality imbalance was greatest at days 14, 28, and 
49 for patients with HABP/VABP/HCABP (cefiderocol 
24%, 31%, and 42% vs BAT 14%, 18%, and 18%). It is 
worth noting that, in the safety population, a greater num-
ber of deaths occurring up to day 3 were reported in the 
cefiderocol arm (cefiderocol 4% vs 0% BAT), which may 
be considered unrelated to study drug efficacy. Moreover, 
a greater number of deaths were reported in the cefider-
ocol arm (9% cefiderocol vs 0% BAT) after day 28 
through the end of study as opposed to BAT, whereas 
proportions were similar from day 4 to day 28 (21% and 
18% in cefiderocol and BAT arms, respectively).
Of note, the difference in 49-day mortality stratified for 
pathogen was the highest for Acinetobacter spp. (50% [21/ 
42] vs 18% [3/17] in cefiderocol and BAT-treated patients, 
respectively), although it is of note that some variables 
indicating severity of presentation or of baseline diseases 
(ICU at randomization, severe renal dysfunction, ongoing 
shock, and shock within 31 days before randomization) 
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were more frequent in the cefiderocol than BAT arms in 
patients with Acinetobacter spp. infections.52
Safety of Cefiderocol
Two Phase 1 studies showed mild, clinically not signifi-
cant adverse events mainly represented by diarrhea and 
skin reactions (maculopapular rash, urticarial) in less than 
20% of patients, with only one treatment discontinuation 
due to urticaria.31,32 In another phase 1 study in healthy 
adult subjects, cefiderocol in normal doses (2 g) and 
supratherapeutic doses (3–4 g) had no apparent clinically 
significant effect on QT and corrected QT (QTcF) 
interval.53
Phase 2 and phase 3 studies confirmed that cefiderocol 
is comparable to other cephalosporins in terms of toler-
ability and safety profile. In the APEKS-cUTI RCT, safety 
was assessed in all randomly assigned individuals who 
received at least one dose of study drug.47 Adverse events 
occurred in 41% (122/300) and 51% (76/148) of patients 
in the cefiderocol and in the imipenem-cilastatin groups, 
respectively, with the majority being mild or moderate. 
Overall, diarrhea and constipation were observed in 7.7% 
of patients in the cefiderocol group and in 10.1% of those 
in the imipenem-cilastatin group. Serious adverse events 
were reported in 5% and 8% of patients in the cefiderocol 
and imipenem-cilastatin groups, respectively. Among ser-
ious adverse events, Clostridioides difficile infection (CDI) 
occurred in one patient in the cefiderocol group and in two 
patients in the imipenem-cilastatin group. One death due 
to cardiac arrest, considered unrelated to study drug by the 
investigator, was reported in the cefiderocol group.
In the APEKS-NP study, adverse events were observed 
in 88% (130/148) and 86% (129/150) in cefiderocol and 
meropenem groups, respectively.48 In both arms, urinary 
tract infections (15.5% and 10.7% in cefiderocol and mer-
openem arms, respectively) and hypokalemia (10.8% and 
15.3% in cefiderocol and meropenem arms, respectively) 
were the most frequently observed adverse events. Serious 
adverse events were observed in 36% (54/148, of which 3 
drug-related) and 30% (45/150, of which 5 drug-related) in 
cefiderocol and meropenem groups, respectively. Among 
patients treated with cefiderocol and meropenem, 4/148 
(3%) and 4/150 (3%) developed C. difficile infection.48
According to the results of the CREDIBLE-CR study, 
the rate of adverse events (evaluated in 101 patients who 
received cefiderocol and 49 patients who received BAT) 
was similar in the two arms, with over 90% of patients 
experiencing at least one adverse event.52 Diarrhea, 
pyrexia, septic shock, vomiting, and hypokalemia were 
the most frequently observed adverse events in both 
groups and diarrhea (19% vs 12%), ALT increased (7% 
vs 0%), AST increased (8% vs 2%), pleural effusion (8% 
vs 2%), and chest pain (6% vs 0%) were observed more 
frequently in the cefiderocol than in the BAT groups. The 
majority of chest pain episodes reported in the cefider-
ocol group were considered to be of non-cardiovascular 
origin and not related to cefiderocol. Most adverse events 
occurred at a low frequency and were considered mani-
festations of the patients’ underlying disease. Indeed, the 
frequency of adverse events considered to be treatment- 
related by the investigator was 15% (15/101) in the 
cefiderocol arm and 22% (11/49) in the BAT arm. 
Diarrhea (2%), abnormal liver function tests (2%), ALT 
increased (3%), and AST increased (3%) were the most 
frequently reported treatment-related, treatment-emergent 
adverse events in the cefiderocol group; while acute 
kidney injury (8%) was the most frequently reported 
treatment-related, treatment-emergent adverse event in 
the BAT group. Serious adverse events were reported 
for 50% and 47% of patients in cefiderocol group and 
BAT group, respectively. Septic shock was the most fre-
quently reported serious adverse event in both cefidero-
col (12%) and BAT (12%) groups. Overall, only 1/101 
patient in the cefiderocol group (1%) experienced 
a treatment-related serious adverse event, that is, an 
increase in transaminases levels which led to study drug 
discontinuation and resolved in 30 days. Conversely, 
treatment-related serious adverse events were observed 
in 5/49 patients in the BAT group (10%). Discontinuation 
due to treatment-related adverse events occurred in 3% 
and 4% of patients in the cefiderocol group and BAT 
group, respectively.
Case Reports and Case Series
Case reports and case series of patients with severe GNB 
infections treated with cefiderocol in compassionate use 
are detailed in Table 3.54–66 All these cases highlight 
unique challenges in managing patients infected by MDR- 
GNB including MBL-producing GNB.
Place in Therapy
Cefiderocol is a first-in-class antibiotic, a siderophore 
intravenous cephalosporin that binds ferric iron and is 
actively transported into the periplasm of GNB.14,67,68 
Beyond its novel mechanism of action, from a practical 
standpoint what makes it attractive for clinicians is the 
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Table 3 Published Case Reports and Case Series of Compassionate Use of Cefiderocol
Age, Sex 
(Reference)
Underlying Condition of the 
Patient
Type of Infection Pathogen 
(in vitro Susceptibility)
Antimicrobial Therapy History Outcome
46, Male57 Partial right great toe amputation treated 
with daptomycin and levofloxacin for 
a vancomycin-resistant Enterococcus 
faecium and Pseudomonas aeruginosa stump 
infection with residual osteomyelitis. 
Hemodialysis-dependent for end-stage 
renal disease, diabetes mellitus, coronary 
disease.
Perforation of the colon with 
intraabdominal abscess. End 
ileostomy and right hemicolectomy. 
Pseudomonas aeruginosa (carbapenem- 
resistant, cefiderocol susceptible), 
Escherichia coli, Bacteroides fragilis.
First line: Meropenem, daptomycin, 
linezolid. 
Second line: Ceftazidime/avibactam, 
polymyxin B, metronidazole. polymyxin 
B was discontinued due to suspect of 
neurotoxicity. 
Third line: cefiderocol plus 
metronidazole.
Decrease in size of intraabdominal 
abscess on day 5 of cefiderocol 
therapy. 
Complete resolution of paracolic 
gutter abscess on day 19 of therapy. 
Discontinuation of treatment after 28 
days therapy.
Adult, male58 Severe H1N1 influenza complicated 
by bilateral pneumonia and 
respiratory failure. 
Intubation and extracorporeal 
membrane oxygenation.
Bacteremia. 
Acinetobacter baumannii (extensively 
drug-resistant, susceptible to colistin); 
Klebsiella pneumoniae (carbapenem 
resistant; colistin, gentamicin, 
ceftazidime/avibactam, and 
cefiderocol susceptible).
First line empiric: piperacillin- 
tazobactam, clarithromycin, linezolid, 
zanamivir. 
Second line: meropenem, 
vancomycin, anidulafungin. 
Third line: colistin, fosfomycin, 
tigecycline, daptomycin. Fourth line: 
cefiderocol, linezolid
Patient conditions rapidly improved 
with resolution of fever and 
normalization of procalcitonin levels 
after start of cefiderocol therapy. 
After 14 days of cefiderocol 
treatment, chest X-rays showed 
complete resolution of lung infiltrates.
78, female56 Hydronephrosis secondary to 
a spontaneous ureteric hematoma. 
She had a past medical history of 
aortic stenosis, ischemic heart 
disease, and cerebral infarction and 
was in remission from breast cancer. 
Thickened aortic valve.
Bacteremia complicated by aortic valve 
endocarditis, Pseudomonas aeruginosa 
(susceptible only to colistin, gentamicin and 
amikacin); (resistant also to ceftazidime/ 
avibactam and ceftolozane/tazobactam. 
No synergy between antipseudomonal 
agents and fosfomycin and rifampicin).
First line: colistin plus gentamicin. 
Second line: colistin plus 
meropenem 
Third line: colistin plus meropenem 
plus cefiderocol for one week 
followed by colistin plus cefiderocol 
for an additional 3 weeks.
Aortic valve replacement was 
performed on day 2 of cefiderocol. 
Blood culture taken the day of 
surgery was negative and persisted 
negative up to day 275.
68, female55 End-stage renal disease secondary to 
diabetes who had been on 
hemodialysis for 8 years. Renal 
transplant complicated by cardiac 
arrest with pulseless electronic 
activity, requiring initiation of 
extracorporeal membrane 
oxygenation and continuous renal 
replacement therapy. Hematoma 
surrounding the kidney allograft and 
placement of abdominal drains
Isolation from peritoneal drain 
cultures and blood. 
Klebsiella pneumoniae positive for both 
NDM-1 and OXA-48 group enzymes 
(resistant to carbapenems, 
ceftazidime/avibactam, meropenem/ 
vaborbactam, and gentamycin; 
susceptible to colistin, tigecycline, 
eravacycline, and cefiderocol).
First line: polymyxin B plus 
tigecycline. 
Second line: polymyxin B, 
ceftazidime/avibactam, aztreonam. 
Third line: polymyxin B, 
ceftazidime/avibactam, cefiderocol 
(1.5 g/12h)
Subsequent blood cultures and peritoneal 
fluid culture were all negative after 
cefiderocol was started, with clinical 
improvement. The patient developed 
vancomycin-resistant Enterococcus faecium 
bacteremia, invasive candidiasis due to 
Candida glabrata, and Clostridioides difficile- 
infection, which were treated with 
daptomycin, caspofungin, and oral 
vancomycin, respectively. 
Eventually the patient developed fatal 
ischemic colitis.
15, male54 Femur fracture after a motor vehicle 
accident, intramedullary pin 
placement.
Recurrent wound infection treated 
with various antibiotics (details not 
available). Chronic osteomyelitis of 
the left femur, with phlegmonous 
changes extending to the skin. 
Pseudomonas aeruginosa (extensively 
drug resistant, susceptible only to 
colistin and cefiderocol), Extended- 
spectrum β-lactamases-producing 




First line empiric: levofloxacin, 
metronidazole, trimethoprim- 
sulfamethoxazole, antibiotic-cement 
nail containing tobramycin and 
vancomycin. 
Second line: cefepime, vancomycin, 
metronidazole. 
Third line: ceftazidime/avibactam 
plus aztreonam 
Fourth line: polymyxin B, 
aztreonam, tigecycline. 
Fifth line: cefiderocol plus 
aztreonam. Aztreonam discontinued 
after two weeks. Bone graft and 
antibiotic nail exchange. Cefiderocol 
was administered for a total of 14 
weeks.
After 9 weeks of cefiderocol therapy 
bone cultures were sterile, and 
a histopathology report showed 
benign bone without associated acute 
or chronic inflammation.
(Continued)
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Table 3 (Continued). 
Age, Sex 
(Reference)
Underlying Condition of the 
Patient
Type of Infection Pathogen 
(in vitro Susceptibility)
Antimicrobial Therapy History Outcome
84, male59 Diabetes mellitus, chronic renal 
failure, previous non-Hodgkin’s 
lymphoma, vascular diseases, hallux 
amputation.
BSI secondary to an infected, wet 
gangrenous left foot, caused by OXA- 
and NDM-producing K. pneumoniae 
(susceptible to colistin, tigecycline, 
and cefiderocol).
First line empiric: piperacillin- 
tazobactam, clindamycin, and 
amikacin, in addition to surgical 
debridement 
Second line: colistin, tigecycline 
Third line: cefiderocol plus colistin, 
then de-escalated to cefiderocol 
monotherapy. Treated with 
cefiderocol for 14 days
Improvement and discharge from 
ICU, subsequent death in a medical 
ward without signs of infection 
relapse
63, male60 Obesity, diabetes mellitus, cardiac 
ischemic disease, gout arthritis.
Para-duodenal pancreatic collection 
with extensively drug resistant (XDR) 
P. aeruginosa (susceptible to colistin 
and cefiderocol) isolated from 
pancreatic pus.
First line: colistin, meropenem 
Second line: cefiderocol
Favorable resolution after 6 weeks of 
treatment. Subsequent isolation of 
a cefiderocol-resistant strain from 
ischial eschar. Subsequent death due 




Patient 1: hypertension, cardiac 
tamponade, septic thrombosis due to 
carbapenemase-producing 
K. pneumoniae 
Patient 2: diabetes mellitus, K. oxytoca 
septic shock 
with bacteraemic pyelonephritis 
Patient 3: Staphylococcus aureus spinal 
implant infection.
Patient 1: BSI due to pan-drug 
resistant Acinetobacter baumannii 
Patient 2: BSI due to colistin- 
susceptible Acinetobacter baumannii, 
complicated by XDR P. aeruginosa 
bacteremia 
Patient 3: wound 
superinfection and spondylodiscitis 
due to XDR A. baumannii (bone 
culture positive)
Patient 1: 
First line empiric: trimethoprim/ 
sulfamethoxazole 
Second line: cefiderocol 
Patient 2: 
First line: colistin 
Second line: cefiderocol 
Patient 3: 
First line: colistin, tigecycline 
Second line: cefiderocol
Patient 1: 
Improvement and discharge from 
ICU, subsequent death in a medical 
ward without signs of infection 
relapse 
Patient 2: 
Resolution of A. baumannii but not 
P. aeruginosa BSI. Subsequent death 
due to intercurrent HSV-1 
disseminated infection 
Patient 3: Bone culture negative after 
21 days of cefiderocol treatment. 
Subsequent completion of a 6-week 
treatment with oral minocycline and 
no signs of relapse at 9-week follow- 
up
10 patients 
(4 males and 
6 females) 
with a mean 
age of 69 
years62
Hypertension (9/10), COVID-19 (5/ 
10), burns (4/10), obesity (2/10), 
bipolar disorder (1/10), bladder 
cancer (1/10), colonic perforation (1/ 
10), intravenous drug use (1/10).
Six BSI and 4 ventilator-associated 
pneumonia (VAP) due carbapenem- 
resistant organisms (7 A. baumannii, 1 
NDM-producing Stenotrophomonas 
maltophilia, 1 NDM-producing 
K. pneumoniae, 1 A. baumannii plus 
NDM-producing K. pneumoniae)
First line: 7 colistin-based 
combination, 1 colistin monotherapy, 
1 tigecycline plus ampicillin- 
sulbactam, 1 ceftazidime/avibactam 
plus aztreonam plus fosfomycin 
Second line: cefiderocol (9 
monotherapy, 1 combined with 
fosfomycin)
Clinical outcome at day 30 was 
favorable in 7/10 cases (70%), 30-day 
mortality was 10% (1/10)
67, male63 Atrial fibrillation, chronic Glaucoma, 
previous left knee replacement, aortic 
stent, right knee replacement.
Acute prosthetic joint infection of the 
right knee managed with 
debridement, antibiotics and implant 
retention (DAIR). Isolation from 
intraoperative material of XDR 
Enterobacter hormaechei (susceptible 
to colistin and tigecycline).
First line empirical: vancomycin, 
piperacillin/tazobactam 
Second line: colistin, tigecycline 
Third line: cefiderocol
Improved, discharged, and treated for 
12 weeks (including 10 weeks of 
cefiderocol monotherapy). Follow-up 
at 12 weeks after end of antibiotic 
treatment showed full recovery.
45, female64 Hemangioblastoma requiring multiple 
neurosurgical interventions, 
esophageal-pleural fistula, esophageal 
perforation repaired with 
jejunostomy and gastrostomy tube 
placement.
Esophageal leak with fistula and 
growth of cefiderocol-susceptible 
XDR P. aeruginosa from plural fluid 
culture, treated surgically and with 
antibiotic therapy.
First line: ceftazidime/avibactam, 
polymyxin B 
Second line: cefiderocol
Full recovery after 3 weeks of 
cefiderocol treatment. Subsequent 
respiratory colonization by 
cefiderocol-resistant XDR 
P. aeruginosa, without infection and 
need for antibiotic therapy.
(Continued)
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displayed in vitro activity against carbapenem-resistant 
A. baumannii and MBL-producing GNB, ie, those MDR- 
GNB for which there are currently no marketed active β- 
lactams (without forgetting its in vitro activity against 
Stenotrophomonas spp. and Burkholderia spp.).69 
Therefore, clinical data from both registrative studies and 
post-marketing experiences are essential to confirm 
whether these promises from in vitro studies could readily 
translate into clinical practice, as well as to delineate 
a precise place in therapy for cefiderocol for the treatment 
of MDR-GNB in the near future. Real-life data would also 
be important for further delineating the safety of cefider-
ocol through Phase 4 surveillance studies.
While the results of the APEKS-cUTI and APEKS- 
NP studies have eventually led to the FDA approval of 
cefiderocol for cUTI and HABP/VABP,47,48 the recent 
EMA approval of cefiderocol for the treatment of infec-
tions due to Gram-negative bacteria in adults with limited 
treatment options70,71 opens doors to its use also for other 
pressing priorities, such as BSI caused by carbapenem- 
resistant A. baumannii or MBL producers, or for its 
empirical use in endemic settings or in colonized patients 
with severe infection. In this regard, it would be critical 
to clarify the remaining issue of the increased mortality 
in cefiderocol-treated patients in the CREDIBLE-CR 
study, especially in the case of infections due to non- 
fermenting GNB. In our opinion, this could be achieved 
in two different, complementary ways: (i) through con-
duction of further RCT (the open-label 
GAMECHANGER RCT, which is comparing cefiderocol 
vs BAT for the treatment of BSI due to GNB, is currently 
recruiting patients [NCT03869437]); (ii) through post- 
marketing observational experiences, which, although 
unable to provide high-quality evidence for guiding treat-
ment due to the inherent limitations of observational 
studies (even when properly adjusting for confounding 
variables) may provide useful hypothesis-generating data 
and clinical success/mortality rates for fine-tuning the 
design of future RCT (perhaps by identifying those cate-
gories of patients that may benefit the most from 
Table 3 (Continued). 
Age, Sex 
(Reference)
Underlying Condition of the 
Patient
Type of Infection Pathogen 
(in vitro Susceptibility)




Patient 1: polytrauma with external 
fixation of an open fracture of the 
tibia 
Patient 2: polytrauma 
Patient 3: blunt thoracic trauma with 
lung injury, hemothorax, rib fractures.
Patient 1: early postoperative, 
polymicrobial, implant-associated 
wound infection due to VIM- 
producing P. aeruginosa, OXA-23- 
producing A. baumannii, and KPC- 
producing Enterobacter cloacae 
Patient 2: postoperative implant- 
associated spine infection due to 
OXA-40 and NDM- producing 
A. baumannii 
Patient 3: pleural empyema due to 
XDR A. baumannii and subsequent 
acute osteomyelitis and urinary tract 
infection due to XDR A. baumannii.
Patient 1: 
Treatment: multiple surgeries plus 
cefiderocol for 2 weeks and colistin 
and ceftazidime-avibactam for 4 
weeks 
Patient 2: 
Treatment: removal of 
osteosynthesis and colistin plus 
cefiderocol for 14 days, then 
cefiderocol monotherapy for a total 
of 6 weeks 
Patient 3: 
Treatment: cefiderocol plus colistin 
(for 14 days) for pleural empyema 
and cefiderocol (6 weeks) for 
osteomyelitis
Patient 1: 
Definite implantation and not signs of 
relapse at 8 weeks of follow-up 
Patient 2: 
Novel osteosynthesis with no signs of 
relapse at 13 weeks of follow-up 
Patient 3: 
No signs of relapse at 6 weeks of 
follow-up
57, male66 Hypertension, diabetes mellitus, left 
tibia and fibula fracture with external 
fixation followed by two surgical 
debridements.
Osteomyelitis of left leg with 
intraoperative cultures positive for 
Enterococcus faecalis, Corynebacterium 
striatum, And XDR A. baumannii.
First line empirical: piperacillin/ 
tazobactam with subsequent addition 
of vancomycin 
Second line: Polymyxin B, 
minocycline, and vancomycin (the 
latter subsequently substituted by 
daptomycin) 
Third line: Daptomycin, 
meropenem, tigecycline 
Fourth line: Daptomycin, 
cefiderocol
Cefiderocol discontinued after 102 
days and no signs of relapse at 128 
days after antibiotics discontinuation.
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cefiderocol administration) should also the 
GAMECHANGER study provide inconclusive evidence.
Until then, some uncertainties in delineating the precise 
place in therapy of cefiderocol for the treatment of MDR- 
GNB infections will remain. Indeed, on the one hand, we 
now have a β-lactam that, at least in vitro, fills the gaps 
against some high-priority MDR-GNB, taking also into 
account the consideration that the increased mortality 
observed in the CREDIBLE-CR study may be merely due 
to chance alone in view of the low power related to the small 
sample size (especially in subgroups) of the CREDIBLE-CR 
study and the current lack of a clear explanation for the 
observed result. On the other hand, further studies remain 
necessary to verify this hypothesis, and cefiderocol should 
not be used indiscriminately. In our opinion, the potential 
advantages of having restored β-lactam activity against 
highly resistant A. baumannii and MBL producers should 
not be wasted while waiting for further evidence. What 
remains largely unclear is whether cefiderocol should be 
used alone or in combination with BAT (eg, polymyxins) 
until more solid evidence is provided. There is still no clear 
answer to this question, which, notably, does not involve the 
classical (and still unresolved) dilemma of the general com-
parison of monotherapy vs combinations for MDR-GNB 
infections in terms of efficacy, but the novel one of not 
using cefiderocol alone considering the possible imbalance 
in mortality registered in the CREDIBLE-CR study. In our 
opinion, it could be ultimately reasonable to consider using 
cefiderocol-including combinations in the case of severe 
clinical presentations, in which a de-escalation rather than 
escalation strategy could be more indicated (authors opinion 
only, not supported by published evidence at the present 
time). The same may apply to the inclusion of cefiderocol 
in empirical regimens in patients with severe infections and 
hospital-level or patient-level risk factors for infections due 
to carbapenem-resistant A. baumannii and/or MBL produ-
cers. Of note, in this scenario reliable and rapid microbiolo-
gical tests for the detection of causative agents and involved 
resistance mechanisms will increasingly play a crucial role 
in the optimization of the empirical use of cefiderocol (initia-
tion/discontinuation) according to antimicrobial and diag-
nostic stewardship principles.72
In conclusion, cefiderocol expands the spectrum of 
MDR-GNB that can be treated again with β-lactams and 
will likely offer a precious addition to the clinician arma-
mentarium. Because of this unique potential, it remains 
essential to provide both RCT (eg, GAMECHANGER) 
and real-life data to improve the clinicians’ ability to 
exploit its benefit in both empirical and targeted treatment 
of MDR-GNB infections.
Acknowledgments
This research was conducted on behalf of ISGRI-SITA 
(Italian Study Group on Resistant Infections of the 
Italian Society of Anti-infective Therapy).
Funding
This work was funded by an unrestricted grant by 
Shionogi Srl. The sponsor had no role in selecting the 
participants, reviewing the literature, defining recommen-
dations, drafting the paper, or in the decision to submit the 
manuscript for publication. All views expressed are solely 
those of the authors.
Disclosure
Outside the submitted work, DRG reports honoraria from 
Stepstone Pharma GmbH and unconditional grants from 
MSD Italia and Correvio Italia.
FP reports grants from Shionogi, during the conduct of 
the study; personal fees from Angelini, Basilea 
Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, 
Nordic Pharma, Novartis, Shionogi, Thermo Fisher, and 
Sandoz, outside the submitted work. Outside the submitted 
work, he has participated in advisory boards and/or 
received speaker honoraria from Angelini, Basilea 
Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & 
Dohme, Novartis, Sanofi Aventis, and Thermo-Fisher.
GMR reports grants, personal fees from Shionogi, dur-
ing the conduct of the study; grants, personal fees, non- 
financial support from Accelerate and Menarini; grants 
from Angelini, bioMérieux, Cepheid, Elitech, Merck, 
Nordic Pharma, Seegene, Zambon, Symcel, DID, Hain 
Lifescience GmbH, GenePoc, Setlance, Biomedical 
Service, Qvella, and Qlinea, outside the submitted work; 
personal fees from Becton Dickinson, Angelini, 
bioMérieux, Cepheid, Merck, Nordic Pharma, Pfizer, 
Venatorx, Zambon, Roche, Thermo Fisher, Beckman 
Coulter, Qpex, and Qiagen, outside the submitted work.
CT reports personal fees from Correvio, Basilea, Hikma, 
MSD, Pfizer, Thermo Fisher, Zambon, Biomerieux, and 
Shionogi, and personal fees from Angelini, outside the sub-
mitted work. Outside the submitted work, he has received 
research grants, and/or been a consultant and/or received 
a fee for speaking from bioMérieux, Zambon, Basilea, 
Merck, Nordic Pharma, Angelini, Thermo Fisher, Biotest, 
Pfizer, Astra Zeneca, Shionogi, Hikma, Avir Pharma, Biotest.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                     
Infection and Drug Resistance 2020:13 4708


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
MT reports personal honoraria for participating in advi-
sory boards and/or for meeting presentations from 
Angelini, Astellas, Menarini, MSD, Nordic Pharma, 
Pfizer, Roche, Shionogi, outside the submitted work.
MB reports grants and personal fees from Shionogi, out-
side the submitted work. Outside the submitted work, he has 
participated in advisory boards and/or received speaker hon-
oraria from Achaogen, Angelini, Astellas, Bayer, Basilea, 
BioMérieux, Cidara, Gilead, Menarini, MSD, Nabriva, 
Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, 
VenatoRx and Vifor and has received study grants from 
Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, 
Gilead, Pfizer and MSD.
References
1. Giani T, Arena F, Pollini S, et al. Italian nationwide survey on 
Pseudomonas aeruginosa from invasive infections: activity of ceftolo-
zane/tazobactam and comparators, and molecular epidemiology of 
carbapenemase producers. J Antimicrob Chemother. 
2018;73:664–671. doi:10.1093/jac/dkx453
2. Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in 
Gram-negative Bacteremia at 173 US Hospitals: retrospective cohort 
analysis of prevalence, predictors, and outcome of resistance to all 
first-line agents. Clin Infect Dis. 2018;67:1803–1814.
3. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of 
the global expansion of Klebsiella pneumoniae carbapenemases. Lancet 
Infect Dis. 2013;13:785–796. doi:10.1016/S1473-3099(13)70190-7
4. Theuretzbacher U. Global antimicrobial resistance in Gram-negative 
pathogens and clinical need. Curr Opin Microbiol. 2017;39:106–112. 
doi:10.1016/j.mib.2017.10.028
5. Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of 
KPC-producing Klebsiella pneumoniae infections. Clin Microbiol 
Infect. 2018;24:133–144. doi:10.1016/j.cmi.2017.08.030
6. Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections 
due to MDR Gram-negative bacteria. Front Med. 2019;6:74. 
doi:10.3389/fmed.2019.00074
7. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of genta-
micin into the alveolar lining fluid of critically ill patients with 
ventilator-associated pneumonia. Chest. 2005;128:545–552. 
doi:10.1378/chest.128.2.545
8. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus 
Guidelines for the Optimal Use of the Polymyxins: endorsed by the 
American College of Clinical Pharmacy (ACCP), European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID), Infectious 
Diseases Society of America (IDSA), International Society for 
Anti-infective Pharmacology (ISAP), Society of Critical Care 
Medicine (SCCM), and Society of Infectious Diseases Pharmacists 
(SIDP). Pharmacotherapy. 2019;39:10–39.
9. Giacobbe DR, Bassetti M, De Rosa FG, et al. Ceftolozane/tazobac-
tam: place in therapy. Expert Rev Anti Infect Ther. 2018;16:307–320. 
doi:10.1080/14787210.2018.1447381
10. Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, merope-
nem/ vaborbactam, or both? Clinical and formulary considerations. 
Clin Infect Dis. 2019;68:519–524. doi:10.1093/cid/ciy576
11. Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of 
ceftazidime-avibactam salvage therapy in patients with infections 
caused by klebsiella pneumoniae carbapenemase-producing K. 
pneumoniae. Clin Infect Dis. 2019;68:355–364. doi:10.1093/cid/ 
ciy492
12. Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and 
meropenem-vaborbactam: two novel carbapenem-beta-lactamase 
inhibitor combinations. Drugs. 2018;78:65–98. doi:10.1007/s40265- 
017-0851-9
13. Yamano Y. In vitro activity of cefiderocol against a broad range of 
clinically important gram-negative bacteria. Clin Infect Dis. 2019;69: 
S544–S551. doi:10.1093/cid/ciz827
14. Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: 
a siderophore cephalosporin with activity against 
carbapenem-resistant and multidrug-resistant gram-negative bacilli. 
Drugs. 2019;79:271–289. doi:10.1007/s40265-019-1055-2
15. Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin 
cefiderocol utilizes ferric iron transporter systems for antibacterial 
activity against Pseudomonas aeruginosa. Antimicrob Agents 
Chemother. 2016;60:7396–7401.
16. Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore 
cephalosporin S-649266 against clinically relevant carbapenemases. 
Antimicrob Agents Chemother. 2016;60:4384–4386. doi:10.1128/ 
AAC.03098-15
17. Poirel L, Kieffer N, Nordmann P. Stability of cefiderocol against 
clinically significant broad-spectrum oxacillinases. Int J Antimicrob 
Agents. 2018;52:866–867. doi:10.1016/j.ijantimicag.2018.11.005
18. Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo 
profiles of a novel siderophore cephalosporin. Clin Infect Dis. 
2019;69:S538–S543. doi:10.1093/cid/ciz826
19. Ito ANT, Kuriowa M, Ishioka Y, et al. Mechanism of cefiderocol high 
MIC mutants obtained in non-clinical FoR studies. Presented at: ID 
Week 2018, Poster 696; San Francisco, CA.
20. Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of 
cefiderocol, a novel siderophore cephalosporin, against 
gram-negative bacteria. Antimicrob Agents Chemother. 2018;62.
21. Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalos-
porin CXA-101 to penicillin-binding proteins of Pseudomonas 
aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–3937. 
doi:10.1128/AAC.00296-10
22. Ito A, Nishikawa T, Ota M, et al. Stability and low induction pro-
pensity of cefiderocol against chromosomal AmpC beta-lactamases 
of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob 
Chemother. 2018;73:3049–3052. doi:10.1093/jac/dky317
23. Kidd JM, Abdelraouf K, Nicolau DP. Development of neutropenic 
murine models of iron overload and depletion to study the efficacy of 
siderophore-antibiotic conjugates. antimicrob agents chemother. 
2019;64. doi:10.1128/AAC.01961-19
24. Clinical and Laboratory Standards Institute. Performance standards for 
anti-microbial susceptibility testing, 30th informational supplement. 
CLSI supplement M100–Ed. 30. Wayne, PA: CLSI; 2020.
25. EUCAST clinical breakpoints cefiderocol addendum. Available from: 
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/ 
Breakpoint_tables/Addenda/Cefiderocol_addendum_20200501.pdf. 
Accessed December 4, 2020.
26. Hackel MA, Tsuji M, Yamano Y, et al. Reproducibility of broth 
microdilution MICs for the novel siderophore cephalosporin, cefider-
ocol, determined using iron-depleted cation-adjusted Mueller-Hinton 
broth. Diagn Microbiol Infect Dis. 2019;94:321–325. doi:10.1016/j. 
diagmicrobio.2019.03.003
27. FDA website. Available from: https://www.fda.gov/drugs/develop 
ment-resources/cefiderocol-injection. Accessed December 4, 2020.
28. Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore 
cephalosporin, cefiderocol, against carbapenem-nonsusceptible and 
multidrug-resistant isolates of gram-negative bacilli collected worldwide 
in 2014 to 2016. Antimicrob Agents Chemother. 2018;62.
29. Kohira N, Hackel MA, Ishioka Y, et al. Reduced susceptibility 
mechanism to cefiderocol, a siderophore cephalosporin, among clin-
ical isolates from global surveillance program (SIDERO-WT-2014). 
J Glob Antimicrob Resist. 2020;22:738–741. doi:10.1016/j. 
jgar.2020.07.009
Infection and Drug Resistance 2020:13                                                                                     submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
4709


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
30. Rolston KVI, Gerges B, Shelburne S, et al. Activity of cefiderocol 
and comparators against isolates from cancer patients. Antimicrob 
Agents Chemother. 2020;64. doi:10.1128/AAC.01955-19
31. Saisho Y, Katsube T, White S, et al. Pharmacokinetics, safety, and 
tolerability of cefiderocol, a novel siderophore cephalosporin for 
gram-negative bacteria, in healthy subjects. Antimicrob Agents 
Chemother. 2018;62. doi:10.1128/AAC.02163-17
32. Katsube T, Echols R, Arjona Ferreira JC, et al. Cefiderocol, 
a siderophore cephalosporin for gram-negative bacterial infections: 
pharmacokinetics and safety in subjects with renal impairment. J Clin 
Pharmacol. 2017;57:584–591. doi:10.1002/jcph.841
33. Katsube T, Miyazaki S, Narukawa Y, et al. Drug-drug interaction of 
cefiderocol, a siderophore cephalosporin, via human drug 
transporters. Eur J Clin Pharmacol. 2018;74:931–938. doi:10.1007/ 
s00228-018-2458-9
34. Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharma-
cokinetics of cefiderocol, a novel siderophore cephalosporin, in 
healthy adult subjects. J Antimicrob Chemother. 
2019;74:1971–1974. doi:10.1093/jac/dkz123
35. Miyazaki S, Katsube T, Shen H, et al. Metabolism, excretion, and 
pharmacokinetics of [(14) C]-cefiderocol (S-649266), a siderophore 
cephalosporin, in healthy subjects following intravenous 
administration. J Clin Pharmacol. 2019;59:958–967. doi:10.1002/ 
jcph.1386
36. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Pharmacodynamics 
of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas 
aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 
2018;51:206–212. doi:10.1016/j.ijantimicag.2017.10.008
37. Nakamura R, Ito-Horiyama T, Takemura M, et al. In vivo pharmaco-
dynamic study of cefiderocol, a novel parenteral siderophore cepha-
losporin, in murine thigh and lung infection models. Antimicrob 
Agents Chemother. 2019;63. doi:10.1128/AAC.02031-18
38. Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol 
against carbapenem-resistant gram-negative bacilli in 
immunocompetent-rat respiratory tract infection models recreating 
human plasma pharmacokinetics. Antimicrob Agents Chemother. 
2017;61. doi:10.1128/AAC.00700-17
39. Chen IH, Kidd JM, Abdelraouf K, Nicolau DP. Comparative in vivo 
antibacterial activity of human-simulated exposures of cefiderocol 
and ceftazidime against stenotrophomonas maltophilia in the murine 
thigh model. Antimicrob Agents Chemother. 2019. doi:10.1128/ 
AAC.01558-19
40. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Humanized expo-
sures of cefiderocol, a siderophore cephalosporin, display sustained 
in vivo activity against siderophore-resistant Pseudomonas 
aeruginosa. Pharmacology. 2018;101:278–284.
41. Kidd JM, Abdelraouf K, Nicolau DP. Efficacy of humanized cefider-
ocol exposure is unaltered by host iron overload in the thigh infection 
model. Antimicrob Agents Chemother. 2019;64. doi:10.1128/ 
AAC.01767-19
42. Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized 
exposures of cefiderocol (S-649266) against a diverse population of 
gram-negative bacteria in a murine thigh infection model. Antimicrob 
Agents Chemother. 2017;61. doi:10.1128/AAC.01022-17
43. Stainton SM, Monogue ML, Tsuji M, et al. Efficacy of humanized 
cefiderocol exposures over 72 hours against a diverse group of 
gram-negative isolates in the neutropenic murine thigh infection 
model. Antimicrob Agents Chemother. 2019;63.
44. Katsube T, Wajima T, Ishibashi T, et al. Pharmacokinetic/pharmaco-
dynamic modeling and simulation of cefiderocol, a parenteral side-
rophore cephalosporin, for dose adjustment based on renal function. 
Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.01381-16
45. Cook AM, Hatton-Kolpek J. Augmented renal clearance. 
Pharmacotherapy. 2019;39:346–354. doi:10.1002/phar.2231
46. Ambrose PG, Lomovskaya O, Griffith DC, et al. beta-Lactamase 
inhibitors: what you really need to know. Curr Opin Pharmacol. 
2017;36:86–93. doi:10.1016/j.coph.2017.09.001
47. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus 
imipenem-cilastatin for the treatment of complicated urinary tract 
infections caused by Gram-negative uropathogens: a phase 2, rando-
mised, double-blind, non-inferiority trial. Lancet Infect Dis. 
2018;18:1319–1328. doi:10.1016/S1473-3099(18)30554-1
48. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus 
high-dose, extended-infusion meropenem for the treatment of 
Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, 
double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2020. 
doi:10.1016/S1473-3099(20)30731-3
49. Shionogi Inc. FDA accepts Shionogi’s supplemental new drug appli-
cation with priority review for FETROJA® (cefiderocol) for the 
treatment of hospital-acquired bacterial pneumonia and ventilator- 
associated bacterial pneumonia; [cited August 12, 2020]. Available 
from: https://www.shionogi.com/us/en/news/2020/6/FDA-Accepts- 
Shionogis-Supplemental-New-Drug-Application-with-Priority- 
Review-for-FETROJA.html. Accessed December 4, 2020.
50. Bassetti M, Ariyasu M, Binkowitz B, et al. Designing A 
pathogen-focused study to address the high unmet medical need 
represented by carbapenem-resistant gram-negative pathogens - the 
international, multicenter, randomized, open-label, Phase 3 
CREDIBLE-CR Study. Infect Drug Resist. 2019;12:3607–3623.
51. Echols R, Ariyasu M, Nagata TD. Pathogen-focused clinical devel-
opment to address unmet medical need: cefiderocol targeting carba-
penem resistance. Clin Infect Dis. 2019;69:S559–S564. doi:10.1093/ 
cid/ciz829
52. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of 
cefiderocol or best available therapy for the treatment of serious 
infections caused by carbapenem-resistant Gram-negative bacteria 
(CREDIBLE-CR): a randomised, open-label, multicentre, 
pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 
2020. doi:10.1016/S1473-3099(20)30796-9
53. Sanabria C, Migoya E, Mason JW, et al. Effect of cefiderocol, 
a siderophore cephalosporin, on QT/QTc interval in healthy adult 
subjects. Clin Ther. 2019;41:1724–1736 e1724.
54. Alamarat ZI, Babic J, Tran TT, et al. Long-term compassionate use of 
cefiderocol to treat chronic osteomyelitis caused by extensively 
drug-resistant Pseudomonas aeruginosa and extended-spectrum-beta- 
lactamase-producing klebsiella pneumoniae in a pediatric patient. 
Antimicrob Agents Chemother. 2020;64.
55. Contreras DA, Fitzwater SP, Nanayakkara DD, et al. Coinfections of 
two strains of NDM-1- and OXA-232-Coproducing Klebsiella pneu-
moniae in a kidney transplant patient. Antimicrob Agents Chemother. 
2020;64.
56. Edgeworth JD, Merante D, Patel S, et al. Compassionate use of 
cefiderocol as adjunctive treatment of native aortic valve endocarditis 
due to extremely drug-resistant Pseudomonas aeruginosa. Clin Infect 
Dis. 2019;68:1932–1934. doi:10.1093/cid/ciy963
57. Stevens RW, Clancy M. Compassionate use of cefiderocol in the 
treatment of an intraabdominal infection due to multidrug-resistant 
Pseudomonas aeruginosa: a case report. Pharmacotherapy. 
2019;39:1113–1118. doi:10.1002/phar.2334
58. Trecarichi EM, Quirino A, Scaglione V, et al. Successful treatment 
with cefiderocol for compassionate use in a critically ill patient with 
XDR Acinetobacter baumannii and KPC-producing Klebsiella pneu-
moniae: a case report. J Antimicrob Chemother. 2019;74:3399–3401. 
doi:10.1093/jac/dkz318
59. Lampejo T, Cherian BP, Tan MGM, et al. Cefiderocol in the treatment 
of systemic carbapenemase-producing multi-drug resistant Klebsiella 
pneumoniae infection. J Glob Antimicrob Resist. 2020. doi:10.1016/j. 
jgar.2020.10.008
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                     
Infection and Drug Resistance 2020:13 4710


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
60. Grande Perez C, Maillart E, Miendje Deyi VY, et al. Compassionate 
use of cefiderocol in a pancreatic abscess and emergence of 
resistance. Med Mal Infect. 2020. doi:10.1016/j.medmal.2020.10.022
61. Oliva A, Ceccarelli G, De Angelis M, et al. Cefiderocol for compas-
sionate use in the treatment of complicated infections caused by 
extensively and pan-resistant Acinetobacter baumannii. J Glob 
Antimicrob Resist. 2020;23:292–296. doi:10.1016/j.jgar.2020.09.019
62. Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy 
for Acinetobacter baumannii and other carbapenem-resistant 
Gram-Negative infections in ICU patients. Clin Infect Dis. 2020. 
doi:10.1093/cid/ciaa1410
63. Siméon S, Dortet L, Bouchand F, et al. Compassionate use of cefi-
derocol to treat a case of prosthetic joint infection due to extensively 
drug-resistant enterobacter hormaechei. Microorganisms. 
2020;8:1236. doi:10.3390/microorganisms8081236
64. Kufel WD, Steele JM, Riddell SW, et al. Cefiderocol for treatment of 
an empyema due to extensively drug-resistant Pseudomonas aerugi-
nosa: clinical observations and susceptibility testing considerations. 
IDCases. 2020;21:e00863. doi:10.1016/j.idcr.2020.e00863
65. Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for extensively 
drug-resistant gram-negative bacterial infections: real-world experi-
ence from a case series and review of the literature. Open Forum 
Infect Dis. 2020;7:ofaa185. doi:10.1093/ofid/ofaa185
66. Dagher M, Ruffin F, Marshall S, et al. Case report: successful rescue 
therapy of extensively drug-resistant acinetobacter baumannii osteo-
myelitis with cefiderocol. Open Forum Infect Dis. 2020;7:ofaa150. 
doi:10.1093/ofid/ofaa150
67. Mollmann U, Heinisch L, Bauernfeind A, et al. Siderophores as drug 
delivery agents: application of the “Trojan Horse” strategy. 
Biometals. 2009;22:615–624. doi:10.1007/s10534-009-9219-2
68. Page MGP. The role of iron and siderophores in infection, and the 
development of siderophore antibiotics. Clin Infect Dis. 2019;69: 
S529–S537. doi:10.1093/cid/ciz825
69. Wu JY, Srinivas P, Pogue JM. Cefiderocol: a novel agent for the 
management of multidrug-resistant gram-negative organisms. Infect 
Dis Ther. 2020;9:17–40. doi:10.1007/s40121-020-00286-6
70. Fectroja. Summary of product characteristics; [cited August 15, 
2020]. Available from: https://www.ema.europa.eu/en/documents/pro 
duct-information/fetcroja-epar-product-information_en.pdf. Accessed 
December 4, 2020.
71. Fetcroja EMA assessment report 27 February 2020. EMA/136096/2.
72. Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests 
for bloodstream infections due to multidrug resistant Gram-negative 
bacteria: therapeutic implications. Clin Microbiol Infect. 
2020;26:713–722. doi:10.1016/j.cmi.2019.09.023
73. Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the side-
rophore cephalosporin, cefiderocol, against a recent collection of 
clinically relevant gram-negative bacilli from North America and 
Europe, including carbapenem-nonsusceptible isolates 
(SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 
2017;61. doi:10.1128/AAC.00093-17
74. Karlowsky JA, Hackel MA, Tsuji M, et al. In vitro activity of 
cefiderocol, a siderophore cephalosporin, against gram-negative 
bacilli isolated by clinical laboratories in North America and 
Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents. 
2019;53:456–466. doi:10.1016/j.ijantimicag.2018.11.007
75. Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of 
cefiderocol, a siderophore cephalosporin, against a recent collection 
of clinically relevant carbapenem-non-susceptible Gram-negative 
bacilli, including serine carbapenemase- and metallo-beta-lactamase- 
producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob 
Agents. 2019;53:177–184.
76. Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity 
of cefiderocol (S-649266), a siderophore cephalosporin, against 
gram-negative bacteria, including carbapenem-resistant nonfermenters 
and enterobacteriaceae with defined extended-spectrum beta-lactamases 
and carbapenemases. Antimicrob Agents Chemother. 2019;63.
77. Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P. Activity of 
the novel siderophore cephalosporin cefiderocol against 
multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol 
Infect Dis. 2017;36:2319–2327. doi:10.1007/s10096-017-3063-z
78. Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of 
a siderophore cephalosporin, S-649266, against enterobacteriaceae 
clinical isolates, including carbapenem-resistant strains. Antimicrob 
Agents Chemother. 2016;60:729–734. doi:10.1128/AAC.01695-15
Infection and Drug Resistance                                                                                                          Dovepress 
Publish your work in this journal 
Infection and Drug Resistance is an international, peer-reviewed open- 
access journal that focuses on the optimal treatment of infection 
(bacterial, fungal and viral) and the development and institution of 
preventive strategies to minimize the development and spread of resis-
tance. The journal is specifically concerned with the epidemiology of  
antibiotic resistance and the mechanisms of resistance development and 
diffusion in both hospitals and the community. The manuscript manage-
ment system is completely online and includes a very quick and fair peer- 
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance 2020:13                                                                                     submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
4711


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
